troglitazone has been researched along with Autoimmune Disease in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fauber, BP | 1 |
| Gobbi, A | 1 |
| Robarge, K | 1 |
| Zhou, A | 1 |
| Barnard, A | 1 |
| Cao, J | 1 |
| Deng, Y | 1 |
| Eidenschenk, C | 1 |
| Everett, C | 1 |
| Ganguli, A | 1 |
| Hawkins, J | 1 |
| Johnson, AR | 1 |
| La, H | 1 |
| Norman, M | 1 |
| Salmon, G | 1 |
| Summerhill, S | 1 |
| Ouyang, W | 1 |
| Tang, W | 1 |
| Wong, H | 1 |
1 other study available for troglitazone and Autoimmune Disease
| Article | Year |
|---|---|
Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.
Topics: Animals; Autoimmune Diseases; Cell Line; Cells, Cultured; Drug Discovery; HEK293 Cells; Humans; Imid | 2015 |